t
AOTI Inc. announced that Senior Independent Director Mr Richard Cotton and Mrs Jane Cotton-Hall purchased a total of 49,110 common shares. These shares were acquired in two transactions: 30,000 shares at 60 pence each on 17 June 2026, and 19,110 shares at 62 pence each on 18 June 2026. Following these purchases, Mr Cotton's beneficial holding, including Mrs Cotton-Hall's, increased to 264,540 Common Shares, representing approximately 0.25% of the Company's issued share capital.
| Date | 19 Jun 2026 |
| Time | 07:00:04 |
| Category | Director/PDMR dealings |
| ID | 9201I |
19 June 2026
AOTI Inc.
(the "Company")
Director/PDMR Shareholding - Share purchase
The Company was informed on 18 June 2026 that Mr Richard Cotton, Senior Independent Director of the Company, and Mrs Jane Cotton-Hall, bought a total of 49,110 common shares of $0.00001 in the capital of the Company ("Common Shares") through the purchase of 30,000 Common Shares at 60 pence per share on 17 June 2026 and 19,110 Common Shares at 62 pence per share on 18 June 2026.
Following the purchases, Mr Cotton's beneficial holding (including that of Mrs Cotton-Hall) and total interest in the Company has increased to 264,540 Common Shares, representing approximately 0.25% of the Company's issued share capital.
The below notification, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||||||||||||||
|
a)
|
Name
|
Richard Cotton / Jane Cotton-Hall |
|||||||||||||||
|
2
|
Reason for the notification
|
||||||||||||||||
|
a)
|
Position/status
|
Senior Independent Director / PCA
|
|||||||||||||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||||||||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||||||||||||||
|
a)
|
Name
|
AOTI Inc. |
|||||||||||||||
|
b)
|
LEI
|
213800ZGCNDSTWIRK687 |
|||||||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||||||||||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Common shares of $0.00001 each
ISIN: US03690C1027 |
|||||||||||||||
|
b)
|
Nature of the transaction
|
Purchase of Common Shares by Mr Cotton and Mrs Cotton-Hall on 17 June 2026 and 18 June 2026
|
|||||||||||||||
|
c)
|
Price(s) and volume(s) |
|
|||||||||||||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
49,110
60.7783p |
|||||||||||||||
|
e)
|
Date of the transaction
|
17 June 2026 and 18 June 2026 |
|||||||||||||||
|
f)
|
Place of the transaction
|
London Stock Exchange |
|||||||||||||||
For further information please contact:
|
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
|
Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
|
Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden
|
+44 (0)20 3100 2000
|
|
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net